Browse > Article
http://dx.doi.org/10.12925/jkocs.2010.27.1.4

Synthesis and Antiproliferative Activity of Quinazolinylmethoxybenzene Derivatives against Melanoma Cell Line  

Lee, Jun-Sang (Biomaterials Center, Korea Institute of Science and Technology)
Yoo, Kyung-Ho (Biomaterials Center, Korea Institute of Science and Technology)
Publication Information
Journal of the Korean Applied Science and Technology / v.27, no.1, 2010 , pp. 20-28 More about this Journal
Abstract
Melanoma is the most aggressive form of skin cancer and is the fastest growing type of cancer in the United States. We report here the synthesis of a novel series of quinazolinylmethoxybenzene derivatives 1a-c and their antiproliferative activities against A375 human melanoma cell line. Among them, urea compound 1a ($IC_{50}\;=\;4.8\;{\mu}M$) having 4-chloro-3-trifluoromethylphenyl moiety showed superior antiproliferative activity to Sorafenib ($IC_{50}\;=\;5.5\;{\mu}M$) as a reference compound. These results will helpful for designing structure of a therapeutic agent for the treatment of melanoma.
Keywords
quinazolinylmethoxybenzenes; synthesis; antiproliferative activity; melanoma cell line;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non-Small-Cell Lung Cancer, J. Clin. Oncol., 22, 3238 (2004).   DOI   ScienceOn
2 S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, Preclinical Overview of Sorafenib, a Multikinase Inhibitor that Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling, Mol. Cancer Ther., 7, 3129 (2008).   DOI   ScienceOn
3 M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg, High-dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients Treated between 1985 and 1993, J. Clin. Oncol., 17, 2105 (1999).   DOI
4 C. M. Anderson, A. C. Buzaid, and S. S. Legha, Systemic Treatments for Advanced Cutaneous Melanoma, Oncology, 9, 1149 (1995).
5 L. Serrone, M. Zeuli, F. M. Sega, and F. Cognetti, Dacarbazine-based Chemotherapy for Metastatic Melanoma: Thirty-year Experience Overview, J. Exp. Clin. Cancer Res., 19, 21 (2000).
6 W. S. Fletcher, D. S. Daniels, V. K. Sondak, B. Dana, R. Townsend, H. E. Hynes, L. F. Hutchins, and J. R. Pancoast, Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma, Am. J. Clin. Oncol., 16, 359 (1993).   DOI   ScienceOn
7 B. S. Nam and K. H. Yoo, Synthesis of New Benzaminoquinoline Derivatives with Antiproliferative Activity against Melanoma Cell Line, J. Kor. Oil Chem. Soc, 26, 297 (2009).   과학기술학회마을
8 L. V. Dubey and I. V. Dubey, Side Reactions of Onium Coupling Reagents BOP and HBTU in the Synthesis of Silica Polymer Supports, Ukr. Bioorg. Acta, 1, 13 (2005).
9 V. Kumar, G. Bhargava, P. D. Dey, and M. P. Mahajan, A Convenient Route to Biologically Important Quinazolines Using N-Arylamino-1,3-diazabuta-1,3-dienes, Curr. Med Chem, 11, 2549 (2004).   DOI   ScienceOn
10 G.-Y. Li, X.-H. Qianc, S.-G. Yan, J.-N. Cui, Q.-C. Huang, R. Zhang, F. -Y. Liu, and D.-W. Cui, Synthesis and Biological Activity of Novel Symmetrical Bis-2-phenyliminothiazolidine Derivatives, J. Med Chem, 48, 3354 (2005).   DOI   ScienceOn
11 D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZD1839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin. Oncol., 29 (Supplement 4), 37 (2002).   DOI   ScienceOn
12 C. Garbe, A. Hauschild, M. Volkenandt, D. Schadendorf, W. Stolz, U. Reinhold, R. D. Kortmann, C. Kettelhack, B. Frerich, U. Keilholz, R. Dummer, G. Sebastian, W. Tilgen, G. Schuler, A. Mackensen, and R. Kaufmann, Evidence and Interdisciplinary Consense-based German Guidelines: Diagnosis and Surveillance of Melanoma, Melanoma Res., 17, 393 (2007).   DOI   ScienceOn
13 J. A. Carlson, J. S. Ross, A. Slominski, G. Linette, J. Mysliborski, J. Hill, and M. Mihm, Jr., Molecular Diagnostics in Melanoma, J. Am Acad. Dermatol., 52, 743 (2005).   DOI   ScienceOn
14 A. C. Buzaid and C. M. Anderson, The Changing Prognosis of Melanoma, Curr. Oncol. Rep., 2, 322 (2000).   DOI   ScienceOn
15 S. A. Rosenburg, M. T. Lotze, J. C. Yang, P. M. Aebersold, W. M. Linehan, C. A. Seipp, and D. E. White, Experience with the Use of High Dose Interleukin-2 in the Treatment of 652 Cancer Patients, Ann. Surg., 210, 474 (1989).   DOI   ScienceOn
16 M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher, Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma, J. Clin. Oncol., 18, 158 (2008).
17 A. Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, J. M. Kirkwood, and F. G. Haluska, B치-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group, J. Clin. Oncol., 24, 4738 (2006).   DOI   ScienceOn
18 D. H. Lawson, Choices in Adjuvant Therapy of Melanoma, Cancer Control, 12, 236 (2005).   DOI
19 B. J. Druker and N. B. Lydon, Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia, J. Clin. Invest, 105, 3 (2000).   DOI   ScienceOn